Biotoxtech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BiotoxtechCo is a South Korean biotech company focused on toxicology testing and safety evaluation services, helping pharmaceutical and chemical developers assess whether their compounds are safe before clinical or commercial use.
It supplies these contract research and testing services to drug developers, chemical manufacturers, and other life-sciences clients. The company is listed on KOSDAQ, South Korea's tech and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Biotoxtech in five facts
What does Biotoxtech do?
BiotoxtechCo is a South Korean biotech company focused on toxicology testing and safety evaluation services, helping pharmaceutical and chemical developers assess whether their compounds are safe before clinical or commercial use.
Where is Biotoxtech listed and in which sector?
Biotoxtech (Korean name: 바이오톡스텍) trades under KRX code 086040 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Biotoxtech?
Its market capitalisation was US$24.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Biotoxtech's latest annual revenue and operating profit?
For fiscal year 2025, Biotoxtech reported revenue of US$35.5M, an operating loss of US$3.6M and a net loss of US$1.2M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 13.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 20
- Early redemption of bonds with warrantsCapital raise · Oct 8
- Report on securities held by executives/major shareholdersSep 23
- Report on large shareholdings (5% rule) (standard)Sep 23
- Report on securities held by executives/major shareholdersSep 7
- Report on large shareholdings (5% rule) (standard)Sep 7
- Report on securities held by executives/major shareholdersSep 1
- Report on large shareholdings (5% rule) (standard)Sep 1
- Report on securities held by executives/major shareholdersAug 31
- Report on large shareholdings (5% rule) (standard)Aug 31
- Early redemption of bonds with warrants
Biotoxtech Co., Ltd. acquired US$4.92M face amount of its 6th-series bonds with warrants (warrant exercise price US$3.36 per share, maturing 2029-07-08) for US$5.12M including interest on July 8, 2026 following the bondholder's exercise of its early redemption option, leaving US$3.06M outstanding, to be cancelled at the Korea Securities Depository.
Capital raise · Jul 8 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Biotoxtech reported consolidated results for FY2025: revenue of US$32.9M (+13.73% year on year), an operating loss of US$3.37M and a net loss of US$1.1M.
Earnings · Feb 26